In this Funding Opportunity Announcement (FOA), the National Institute of Mental Health (NIMH), the National Institute on Drug Abuse (NIDA), and the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), and the Agency for Healthcare Research and Quality, encourage research on women's mental health in relation to pregnancy and the postpartum period. As illustrated by a few highly publicized cases, the consequences of severe untreated postpartum depression and psychosis can be devastating for individuals, families, and communities. A recent evidence-based practice report from the Agency for Healthcare Research and Quality noted that depression is also prevalent during pregnancy as well as the postpartum period, therefore research that occurs throughout pregnancy and the postpartum period (the perinatal period) is encouraged.
Medications Development for the Treatment of Pregnant/Postpartum Women with Substance Related Disorders and/or In Utero Substance Exposed Neonates
Agency:NIH/NIAAA/NICHD/NIDA
Number:R01 PA-09-106
R21 PA-09-107
Deadline:R01 5 JUN, 5 OCT, 5 FEB until 8 MAY 2012
The purpose of this FOA is to foster the development of novel pharmacological strategies for the treatment of pregnant/postpartum women with Substance Related Disorders (SRDs) and/or in utero substance exposed neonates.To that end, this FOA issued by NIDA, National Institutes of Health, will encourage applications to implement preclinical and clinical research directed towards: 1) the identification, evaluation, and development of safe and effective novel pharmacotherapies (e.g., new chemical entities or immunotherapies) for the treatment of pregnant/postpartum women with SRDs and/or in utero substance exposed neonates, and/or 2) the evaluation of the safety and efficacy of FDA approved medications (e.g., medications approved for a different indication) for the treatment of pregnant/postpartum women with SRDs and/or in utero substance exposed neonates.
